BEAM - Intellia and Sangamo preferred as RBC extends gene editing coverage

Having initiated CRISPR Therapeutics ([[CRSP]] -6.0%) with a sector perform rating in October, RBC Capital Markets has added four more gene-editing stocks into its coverage.The analysts Luca Issi and Lisa Walter have issued outperform ratings on Intellia Therapeutics ([[NTLA]] -2.9%) and Sangamo Therapeutics ([[SGMO]] -2.2%). And Editas Medicine ([[EDIT]] -3.5%) and Beam Therapeutics ([[BEAM]] -3.7%) were both rated sector perform.Given the ‘broadest/ deepest gene-editing toolbox in the space,’ Intellia is poised to close the valuation gap with CRISPR, the analysts argue giving the stock a price target of $110.00 per share to indicate ~49.1% upside to the last close.Intellia’s Phase 1 study of NTLA-2001 for transthyretin amyloidosis ("ATTR") is expected to yield topline data in 2021 which according to analysts is a major data readout with implications across the space.Sangamo has trailblazed the gene-editing field, the analysts argue giving the stock a price target of $22.00 per share to imply ~89.2% upside

For further details see:

Intellia and Sangamo preferred as RBC extends gene editing coverage